3 ms·
Absolutely, these kind of preliminary results need replication to be believed, but I'm reminded of the early days when MDMA was touted as a treatment for PTSD.
by EA-3167 3y ago
Absolutely, these kind of preliminary results need replication to be believed, but I'm reminded of the early days when MDMA was touted as a treatment for PTSD. Happily that's since held up to scrutiny.
I hope the delay with Ibogaine isn't as long as it was for MDMA.
- GuB-42 3y agoIbogaine is not a party drug like MDMA, it is not considered addictive, and is often an unpleasant experience. In fact, it may even have anti-addiction properties. So, probably easier to get a pass. On the other hand, it doesn't look good from a toxicity standpoint, several people have died from it. It doesn't mean it can't work as treatment, after all, Tylenol can be deadly, but it may take some time to assess the risks. Also, it is notoriously hard to predict the effects of psychedelics, which can be a problem for designing a treatment.
- brnaftr361 3y agoI've never been wholly convinced that such a treatment merits design or engineering, beyond implicit safety rails and dose optimization - even then there are instances where the bumpers had ought to be removed entirely. It has however been quite some long time since I read on ibogaine, and if I recall correctly the effects lasted three days, which would indeed merit some check-in.
- more_corn 3y agoThe heart problems probably make it a non-starter.